Skip to main content
SpringerLink
Log in

Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia

  • Published:
Human Physiology Aims and scope Submit manuscript

Abstract

Incretins are hormones with a wide range of biological activity. We studied the ratio of the glycemic effect of the glucagon-like peptide-1 mimetic and its effect on the renal excretion of sodium and water. It was found that both effects depend on the initial blood concentration of glucose. In normoglycemia, exenatide had no effect on blood sugar level, but it significantly increased urinary sodium excretion and reabsorption of solute-free water. In hyperglycemia the blood glucose concentration was normalized by exenatide, while the excretion of sodium by the kidneys and the reabsorption of solute-free water were increased to a small extent. This pattern was found both in patients with type 2 diabetes mellitus and in rats with hyperglycemia induced by intraperitoneal injection of glucose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

Similar content being viewed by others

REFERENCES

  1. Shestakova, M.V. and Vikulova, O.K., Modern pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1), Sakharnyi Diabet, 2007, no. 1, p. 9.

  2. Holst, J.J., Deacon, C.F., Vilsboll, T., et al., Glucagon-like peptide-1, glucose homeostasis and diabetes, Trends Mol. Med., 2008, vol. 14, no. 4, p. 161.

    Article  CAS  Google Scholar 

  3. Galstyan, G.R., Karataeva, E.A., and Yudovich, E.A., Evolution of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes, Sakharnyi Diabet, 2017, vol. 20, no. 4, p. 286.

    Google Scholar 

  4. Biryukova, E.V. and Yakubova, T.R., Byetta: past, present, and future, Eff. Farmakoter., 2015, no. 11, p. 34.

  5. Gallwitz, B., Novel therapeutic approaches in diabetes, Endocrinol. Dev., 2016, vol. 31, p. 43.

    Article  CAS  Google Scholar 

  6. Nauck, M.A. and Meier, J.J., Incretin hormones: their role in health and disease, Diabetes Obes. Metab., 2018, vol. 20, suppl. 1, p. 5.

    Article  CAS  Google Scholar 

  7. Natochin, Yu.V., Marina, A.S., and Kutina, A.V., The role of incretin as an integrator of sodium and water balance regulation, Dokl. Biol. Sci., 2014, vol. 458, no. 1, p. 271.

    Article  Google Scholar 

  8. Crajoinas, R.O., Oricchio, F.T., Pessoa, T.D., et al., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1, Am. J. Physiol. Renal Physiol., 2011, vol. 301, no. 2, p. F355.

    Article  CAS  Google Scholar 

  9. Kutina, A.V., Golosova, D.V., Marina, A.S., et al., Role of Vasopressin in the regulation of renal sodium excretion: interaction with glucagon-like peptide-1, J. Neuroendocrinol., 2016, vol. 28, no. 4. https://doi.org/10.1111/jne.12367

  10. Shutskaya, Zh.V., Shakhmatova, E.I., Kuznetsova, A.A., and Natochin, Yu.V., The role of the kidneys in the regulation of osmolality and concentrations of cations in the blood serum in hyperglycemia, Hum. Physiol., 2008, vol. 34, no. 5, p. 601.

    Article  CAS  Google Scholar 

  11. Shakhmatova, E.I., Pimenova, E.V., and Shutskaya, Zh.V., The influence of Byetta (Exenatide) on the osmoregulatory function of the kidneys in humans with diabetes mellitus, Eksp. Klin. Farmakol., 2014, vol. 77, no. 3, p. 24.

    CAS  PubMed  Google Scholar 

  12. De Vogel-van den Bosch, J., Hoeks, J., Timmers, S., et al., The effects of long- or medium-chain fat diets on glucose tolerance and myocellular content of lipid intermediates in rats, Obesity, 2011, vol. 19, no. 4, p. 792.

    Article  CAS  Google Scholar 

  13. Tonneijck, L., Smits, M.M., Muskiet, M.H., et al., Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomized, double-blind, placebo-controlled trial, Diabetologia, 2016, vol. 59, no. 7, p. 1412.

    Article  CAS  Google Scholar 

  14. Tonneijck, L., Smits, M.M., Muskiet, M.H., et al., Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 2016, vol. 39, no. 11, p. 2042.

    Article  CAS  Google Scholar 

  15. von Scholten, B.J., Hansen, T.W., Goetze, J.P., et al., Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes, J. Diabetes Complications, 2015, vol. 29, no. 5, p. 670.

    Article  Google Scholar 

  16. Skov, J., Pedersen, M., Holst, J.J., et al., Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial, Diabetes Obes. Metab., 2016, vol. 18, no. 6, p. 581.

    Article  CAS  Google Scholar 

  17. Muskiet, M.H., Tonneijck, L., Smits, M.M., et al., Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men, Diabetes Obes. Metab., 2016, vol. 18, no. 2, p. 178.

    Article  CAS  Google Scholar 

  18. Schlatter, P., Beglinger, C., Drewe, J., and Gutmann, H., Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells, Regul. Pept., 2007, vol. 141, no. 1–3, p. 120.

    Article  CAS  Google Scholar 

  19. Thomson, S.C., Kashkouli, A., and Singh, P., Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat, Am. J. Physiol. Renal Physiol., 2013, vol. 304, no. 2, p. F137.

    Article  CAS  Google Scholar 

  20. Roscoe, J.M., Halperin, M.L., Rolleston, F.S., and Goldstein, M.B., Hyperglycemia-induced hyponatremia: metabolic considerations in calculation of serum sodium depression, Can. Med. Assoc. J., 1975, vol. 112, no. 4, p. 452.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Mozaffari, M.S. and Schaffer, S.W., Impaired saline-stimulated diuresis and natriuresis in the conscious hypertensive glucose-intolerant rat, Am. J. Hypertens., 2002, vol. 15, no. 1, p. 58.

    Article  CAS  Google Scholar 

  22. Marwaha, A. and Lokhandwala, M.F., Diminished natriuretic response to dopamine D1 receptor agonist, SKF-38393 in obese Zucker rats, Clin. Exp. Hypertens., 2003, vol. 25, no. 8, p. 509.

    Article  CAS  Google Scholar 

  23. Arumugam, S., Sreedhar, R., Miyashita, S., et al., Comparative evaluation of torasemide and furosemide on rats with streptozotocin-induced diabetic nephropathy, Exp. Mol. Pathol., 2014, vol. 97, no. 1, p. 137.

    Article  CAS  Google Scholar 

  24. Brands, M.W. and Manhiani, M.M., Sodium-retaining effect of insulin in diabetes, Am. J. Physiol.-Regul. Integr. Comp. Physiol., 2012, vol. 303, no. 11, p. R1101.

    Article  CAS  Google Scholar 

  25. Ueda-Nishimura, T., Niisato, N., Miyazaki, H., et al., Synergic action of insulin and genistein on Na+/K+/2Cl– cotransporter in renal epithelium, Biochem. Biophys. Res. Commun., 2005, vol. 332, no. 4, p. 1042.

    Article  CAS  Google Scholar 

  26. Chavez-Canales, M., Arroyo, J.P., Ko, B., et al., Insulin increases the functional activity of the renal NaCl cotransporter, J. Hypertens., 2013, vol. 31, no. 2, p. 303.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Blazer-Yost, B.L., Esterman, M.A., and Vlahos, C.J., Insulin-stimulated trafficking of ENaC in renal cells requires PI3-kinase activity, Am. J. Physiol., Cell. Physio-l., 2003, vol. 284, p. C1645.

    Article  CAS  Google Scholar 

  28. Irsik, D.L., Blazer-Yost, B.L., Staruschenko, A., and Brands, M.W., The normal increase in insulin after a meal may be required to prevent postprandial renal sodium and volume losses, Am. J. Physiol.-Regul. Integr. Comp. Physiol., 2017, vol. 312, no. 6, p. R965.

    Article  Google Scholar 

Download references

Funding

This study was carried out in the framework of the state contract of the Federal Agency for Scientific Organizations of Russia (state registration no. АААА-А18-118012290371-3) and supported in part by the Russian Foundation for Fundamental Research, project no. 17-04-01216.

Author information

Authors and Affiliations

  1. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia

    A. V. Kutina, E. V. Balbotkina, T. A. Karavashkina & E. I. Shakhmatova

Authors
  1. A. V. Kutina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. V. Balbotkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. A. Karavashkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. I. Shakhmatova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. V. Kutina.

Ethics declarations

Conflict of interests. The authors declare that they have no conflict of interest connected with the publication of this article.

Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies involving human participants were in accordance with the biomedical ethics principles formulated in the 1964 Helsinki Declaration and its later amendments and approved by the bioethics commission of the Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences (St. Petersburg). Informed consent was obtained from all individual participants involved in the study after their being explained the potential risks and advantages, as well as the essence of the future study.

Additional information

Translated by E. Babchenko

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kutina, A.V., Balbotkina, E.V., Karavashkina, T.A. et al. Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia. Hum Physiol 45, 685–692 (2019). https://doi.org/10.1134/S036211971904008X

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S036211971904008X

Keywords:

Search

Navigation